Olmesartan-Induced Sprue Like Enteropathy

Detalhes bibliográficos
Autor(a) principal: Carneiro,Liliana
Data de Publicação: 2016
Outros Autores: Moreira,Albina, Pereira,Adelina, Andrade,Carina, Soares,José, Silva,Artur
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000200008
Resumo: Chronic diarrhoea is a common clinical problem in gastroenterology practice and often it is difficult to diagnose the cause. Villous atrophy is not specific and the rarer possibility of drug-induced enteritis should always be considered. Olmesartan has recently been described as a cause of drug-induced enteropathy characterized by chronic diarrhoea and varying degrees of duodenal mucosa atrophy resembling celiac disease. We describe two cases of sprue-like enteropathy in patients treated with olmesartan for arterial hypertension several years before the onset of symptoms. Patients presented severe diarrhoea and significant weight loss, and both had histological evidence of intestinal villous atrophy. The clinical signs completely resolved after drug withdrawal. Olmesartan-induced enteropathy is a new clinical entity that must be included in the differential diagnosis of villous atrophy with negative celiac serology. The clinical and histological alterations easily and completely resolve after drug discontinuation, restoring quality of life to patients and avoiding unnecessary investigation.
id RCAP_dda404646410ab68591717ee081dbcc3
oai_identifier_str oai:scielo:S2341-45452016000200008
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Olmesartan-Induced Sprue Like EnteropathyAtrophy/chemically inducedDiarrhoea/chemically inducedOlmesartanIntestinal MucosaChronic diarrhoea is a common clinical problem in gastroenterology practice and often it is difficult to diagnose the cause. Villous atrophy is not specific and the rarer possibility of drug-induced enteritis should always be considered. Olmesartan has recently been described as a cause of drug-induced enteropathy characterized by chronic diarrhoea and varying degrees of duodenal mucosa atrophy resembling celiac disease. We describe two cases of sprue-like enteropathy in patients treated with olmesartan for arterial hypertension several years before the onset of symptoms. Patients presented severe diarrhoea and significant weight loss, and both had histological evidence of intestinal villous atrophy. The clinical signs completely resolved after drug withdrawal. Olmesartan-induced enteropathy is a new clinical entity that must be included in the differential diagnosis of villous atrophy with negative celiac serology. The clinical and histological alterations easily and completely resolve after drug discontinuation, restoring quality of life to patients and avoiding unnecessary investigation.Sociedade Portuguesa de Gastrenterologia2016-04-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/reporttext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000200008GE-Portuguese Journal of Gastroenterology v.23 n.2 2016reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000200008Carneiro,LilianaMoreira,AlbinaPereira,AdelinaAndrade,CarinaSoares,JoséSilva,Arturinfo:eu-repo/semantics/openAccess2024-02-06T17:33:40Zoai:scielo:S2341-45452016000200008Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:35:56.739762Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Olmesartan-Induced Sprue Like Enteropathy
title Olmesartan-Induced Sprue Like Enteropathy
spellingShingle Olmesartan-Induced Sprue Like Enteropathy
Carneiro,Liliana
Atrophy/chemically induced
Diarrhoea/chemically induced
Olmesartan
Intestinal Mucosa
title_short Olmesartan-Induced Sprue Like Enteropathy
title_full Olmesartan-Induced Sprue Like Enteropathy
title_fullStr Olmesartan-Induced Sprue Like Enteropathy
title_full_unstemmed Olmesartan-Induced Sprue Like Enteropathy
title_sort Olmesartan-Induced Sprue Like Enteropathy
author Carneiro,Liliana
author_facet Carneiro,Liliana
Moreira,Albina
Pereira,Adelina
Andrade,Carina
Soares,José
Silva,Artur
author_role author
author2 Moreira,Albina
Pereira,Adelina
Andrade,Carina
Soares,José
Silva,Artur
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Carneiro,Liliana
Moreira,Albina
Pereira,Adelina
Andrade,Carina
Soares,José
Silva,Artur
dc.subject.por.fl_str_mv Atrophy/chemically induced
Diarrhoea/chemically induced
Olmesartan
Intestinal Mucosa
topic Atrophy/chemically induced
Diarrhoea/chemically induced
Olmesartan
Intestinal Mucosa
description Chronic diarrhoea is a common clinical problem in gastroenterology practice and often it is difficult to diagnose the cause. Villous atrophy is not specific and the rarer possibility of drug-induced enteritis should always be considered. Olmesartan has recently been described as a cause of drug-induced enteropathy characterized by chronic diarrhoea and varying degrees of duodenal mucosa atrophy resembling celiac disease. We describe two cases of sprue-like enteropathy in patients treated with olmesartan for arterial hypertension several years before the onset of symptoms. Patients presented severe diarrhoea and significant weight loss, and both had histological evidence of intestinal villous atrophy. The clinical signs completely resolved after drug withdrawal. Olmesartan-induced enteropathy is a new clinical entity that must be included in the differential diagnosis of villous atrophy with negative celiac serology. The clinical and histological alterations easily and completely resolve after drug discontinuation, restoring quality of life to patients and avoiding unnecessary investigation.
publishDate 2016
dc.date.none.fl_str_mv 2016-04-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000200008
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000200008
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000200008
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
dc.source.none.fl_str_mv GE-Portuguese Journal of Gastroenterology v.23 n.2 2016
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137412270522368